Compare GFS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFS | RVMD |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 19.2B |
| IPO Year | 2017 | N/A |
| Metric | GFS | RVMD |
|---|---|---|
| Price | $48.98 | $96.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | $45.08 | ★ $120.47 |
| AVG Volume (30 Days) | ★ 3.9M | 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $9.90 | $411.49 |
| P/E Ratio | $29.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.69 | $34.00 |
| 52 Week High | $50.98 | $124.49 |
| Indicator | GFS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 61.59 | 48.24 |
| Support Level | $39.96 | $93.39 |
| Resistance Level | $49.36 | $101.00 |
| Average True Range (ATR) | 2.10 | 3.12 |
| MACD | 0.58 | 0.21 |
| Stochastic Oscillator | 86.36 | 51.05 |
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and has about 13,000 staff.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.